Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN
Ferring Pharmaceuticals has announced that the first patient in the United States suffering from high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has been ... Read More
Ferring bags Adstiladrin FDA approval in non-muscle invasive bladder cancer
Swiss biopharmaceutical company Ferring Pharmaceuticals has received approval for its Adstiladrin (nadofaragene firadenovec-vncg) gene therapy from the US Food and Drug Administration (FDA) for the treatment ... Read More
Ferring Pharmaceuticals gets Rebyota FDA approval for recurring CDI
Rebyota FDA approval : Ferring Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Rebyota (fecal microbiota, live-jslm), a microbiota-based live ... Read More
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy
Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in ... Read More
Ferring Pharmaceuticals launches Nocdurna in US to treat nocturia
Ferring Pharmaceuticals has announced the launch of Nocdurna (desmopressin acetate) in the United States, marking a significant advancement in the treatment of nocturia caused by ... Read More